Related Experiment Videos

Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial

Nobuyuki Sato1, Yasuaki Saijo, Naoyuki Hasebe

  • 1Department of Cardiolog, Asahikawa Medical University, Hokkaido, Japan.

International Heart Journal
|August 11, 2012
PubMed

Insights

This study compared adding hydrochlorothiazide or amlodipine to angiotensin receptor blockers in elderly patients with hypertension. Results will guide optimal combination therapy choices for this population.

Area of Science:

  • Cardiology
  • Geriatrics
  • Pharmacology

Background:

  • Combination therapy with angiotensin receptor blockers (ARBs) and calcium channel blockers (CCBs) or diuretics is common for hypertension.
  • Elderly hypertensive patients often require optimized treatment strategies.

Purpose of the Study:

  • To compare the efficacy of adding hydrochlorothiazide (a diuretic) versus amlodipine (a CCB) to ARB therapy in elderly patients (aged ≧ 65 years) with uncontrolled hypertension.
  • To evaluate the impact of these combination therapies on blood pressure, albuminuria, and cognitive function.

Main Methods:

  • A multicentre, randomized, open-label, parallel comparison study.
  • Elderly hypertensive outpatients on ARBs with blood pressure < 140/90 mmHg were randomized to switch to losartan/hydrochlorothiazide or amlodipine plus ARBs.
  • Primary endpoint: change in systolic and diastolic blood pressure after 3 months.
  • Secondary endpoints: changes in blood pressure, albuminuria, laboratory values, and cognitive function (MMSE) at 1 year.

Main Results:

  • Data on blood pressure changes, albuminuria, laboratory values, and cognitive function are being collected.
  • The CAMUI trial aims to provide comparative data on these combination therapies.

Conclusions:

  • The study is expected to offer evidence-based guidance for selecting the most effective combination therapy for elderly patients with hypertension.
  • Findings will inform clinical practice regarding antihypertensive medication choices in older adults.

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...